Results 201 to 210 of about 23,423,883 (325)
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu +5 more
wiley +1 more source
Monitoring structural change and drug release of responsive nanoparticles using polarity-sensitive fluorophores. [PDF]
Gao Y, McDonald PW, Ritchie C, Such GK.
europepmc +1 more source
Structural change and spatial pattern of intentional travel groups: A case study of metro riders in Hong Kong. [PDF]
Zhou M, Zhou J.
europepmc +1 more source
Clinical analysis reveals significant dysregulation of FGFRL1 in esophageal cancer (EC) patients. RNAi‐coupled next‐generation sequencing (NGS) and in vitro study reveal FGFRL1‐mediated EC progression via EMT, PI3K/Akt, and Notch pathways. Functional assays confirm its role in tumor growth, migration, and invasion.
Aprajita Srivastava +3 more
wiley +1 more source
Methodological approaches to structural change: epidemiology and the case for reparations. [PDF]
Lawrence JA +5 more
europepmc +1 more source
Commentary: Imaging in macular telangiectasia type 2 - Correlating structural change with vision. [PDF]
Bhende M.
europepmc +1 more source
We investigated the toxicity of 12 active compounds commonly found in herbal weight loss supplements (WLS) using human liver and colon cell models. Epigallocatechin‐3‐gallate was the only compound showing significant toxicity. Metabolic profiling revealed protein degradation, disrupted energy and lipid metabolism suggesting that the inclusion of EGCG ...
Emily C. Davies +3 more
wiley +1 more source
Tracking the structural change of the predissociating molecule near the transition state. [PDF]
Kim J, Kang M, Yoon JH, Kim SK.
europepmc +1 more source
[Structural Change: Industry's Fear of the Future]. [PDF]
von Werder M, Rukwid R.
europepmc +1 more source
NF90–NF45 functions as a negative regulator of methyltransferase‐like 3/14 (METTL3/14)‐mediated N6‐methyladenosine (m6A) modification on primary microRNAs (pri‐miRNAs). NF90–NF45 binds to anti‐oncogenic pri‐miRNAs and inhibits their m6A modification, thereby suppressing the biogenesis of anti‐oncogenic miRNAs.
Takuma Higuchi +6 more
wiley +1 more source

